Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Short-Term Debt: ¥6,256 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600521 Zhejiang Huahai Pharmaceutical Co Ltd SHSE:600521
88 GF Score
Price ¥16.66
GF Value ¥17.14
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Zhejiang Huahai Pharmaceutical Co Short-Term Debt?

Zhejiang Huahai Pharmaceutical Co SHSE:600521 +3.22% 88 Short-Term Debt is ¥6,256 Mil as of Jun. 2026. GuruFocus rates SHSE:600521 with a GF Score™ of 88/100 and a GF Value™ of ¥17.14 (Fairly Valued). The stock has 8 warning signs investors should review.

Zhejiang Huahai Pharmaceutical Co's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥6,256 Mil.

Zhejiang Huahai Pharmaceutical Co's quarterly Short-Term Debt increased from Dec. 2025 (¥6,748 Mil) to Mar. 2026 (¥6,945 Mil) but then declined from Mar. 2026 (¥6,945 Mil) to Jun. 2026 (¥6,256 Mil).

Zhejiang Huahai Pharmaceutical Co's annual Short-Term Debt increased from Dec. 2023 (¥3,385 Mil) to Dec. 2024 (¥3,662 Mil) and increased from Dec. 2024 (¥3,662 Mil) to Dec. 2025 (¥6,748 Mil).

Zhejiang Huahai Pharmaceutical Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Zhejiang Huahai Pharmaceutical Co Short-Term Debt Related Terms

Zhejiang Huahai Pharmaceutical Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Zhejiang Huahai Pharmaceutical Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Huahai Pharmaceutical Co Short-Term Debt Chart

Zhejiang Huahai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,424.59 2,518.49 3,385.17 3,662.37 6,747.72

Zhejiang Huahai Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,424.57 4,302.57 6,747.72 6,945.08 6,255.74
SHSE:600521
88GF Score
Zhejiang Huahai Pharmaceutical Co Ltd SHSE:600521
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥6,256 Mil mean?
Zhejiang Huahai Pharmaceutical Co (SHSE:600521) has a Short-Term Debt of ¥6,256 Mil as of Jun. 2026.
Is Zhejiang Huahai Pharmaceutical Co's Short-Term Debt too high?
Zhejiang Huahai Pharmaceutical Co's current Short-Term Debt is ¥6,256 Mil. Overall, Zhejiang Huahai Pharmaceutical Co has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Huahai Pharmaceutical Co's Short-Term Debt compare to ZTS?
Zhejiang Huahai Pharmaceutical Co's Short-Term Debt of ¥6,256 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Zhejiang Huahai Pharmaceutical Co's current Short-Term Debt is ¥6,256 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Huahai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Huahai Pharmaceutical Co (SHSE:600521) is currently considered Fairly Valued. The stock's GF Value™ is ¥17.14, compared to a current price of ¥16.66 — trading 2.8% below its estimated fair value. The current Short-Term Debt is ¥6,256 Mil. Zhejiang Huahai Pharmaceutical Co's overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Zhejiang Huahai Pharmaceutical Co (SHSE:600521), the current Short-Term Debt is ¥6,256 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Huahai Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥16.66 is trading 2.8% below its estimated GF Value™ of ¥17.14. GuruFocus considers Zhejiang Huahai Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600521:

  • Short-Term Debt: ¥6,256 Mil
  • GF Value™: ¥17.14 vs. price of ¥16.66 (2.8% below fair value)
  • GF Score™: 88/100 with 8 warning signs

No single metric tells the full story. See the SHSE:600521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Huahai Pharmaceutical Co Business Description

Address Xunqiao, Zhejiang Province, Linhai, CHN, 317024
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in research and development, production, and sales of multi-dosage preparations, biological drugs, innovative drugs, and specialty APIs. The company's products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, torsemide injection, and others.
88GF Score

Get the complete analysis for SHSE:600521

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.66
Price
¥17.14
GF Value